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Abstract
Objective: To determine the utility of the first-trimester fetal nuchal translucency (NT) thickness in the prediction of fetal cardiac
malformations. Design: Retrospective study. Setting: Department of Obstetrics and Gynecology and Medical Genetics, University of
Szeged. Methods: The pre- and postnatal course and outcome, and the relationship between the first-trimester fetal NT thickness and fetal
congenital heart defects (CHDs) in 4309 pregnancies ended up with birth or therapeutic abortion between January 1998 and June 2000 were
registered. Prenatal care included first- and second-trimester fetal sonography at weeks 10–13 and 18–20, respectively. Results: 4251 births
and 58 first- and second-trimester therapeutic abortions due to lethal congenital malformations or chromosomal abnormalities were
recorded. Altogether 209 (4.9%) congenital malformations were detected, 39 (18.7%) of which were heart defects with normal karyotype.
At birth, 151 congenital malformations were diagnosed, 34 of them were known prenatally. The prevalence of CHDs was 9 per 1000
pregnancies. The measurement of fetal NT thickness was available in 35 of the 39 fetuses with heart defects: it was 3 mm in 18 (51.4%)
and <3 mm in 17 (48.6%). A sensitivity of 51.4% was found at a cutoff of 3 mm. Conclusions: An increased NT thickness in
chromosomally normal fetuses was found to be highly associated with CHDs and identified in more than half of the affected cases.
Furthermore, an increased NT of 3 mm can be regarded a selection criterion for early second-trimester targeted fetal echocardiography
and for increased fetal and neonatal surveillance. # 2002 Elsevier Science Ireland Ltd. All rights reserved.
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1. Introduction
Congenital heart defects (CHDs) are the most common
congenital abnormalities, with a birth prevalence of 8–10 per
1000 [1–3]. They account for 30% of all congenital mal-
formations and are responsible for a significant proportion of
fetal and neonatal mortality [3]. The high prevalence of
CHDs in pre- and perinatal mortality underlines the need for
prenatal screening.
Major abnormalities of the heart and the great vessels can
be identified via a routine second-trimester ultrasound scan
between weeks 16 and 22; examination of the four-chamber
view of the heart allows a detection rate of 26% [4].
Combined examination of the four-chamber and outflow
tract views of the heart in the second-trimester led to the
identification of 61% of the fetuses with CHDs [5]. The
detection rate was further increased to 81% when transva-
ginal ultrasound was used to predict fetal cardiac defects in a
small series [6–9].
An increased fetal NT in the first-trimester was reported to
be a highly efficient ultrasound marker for aneuploidies
[10,11], and was also found to be highly suggestive of fetal
cardiac [11–14] and other structural abnormalities [15–17].
At the regional perinatal center in Szeged, the mean birth
prevalence of CHDs during the past 5 years has been 8.2 per
1000 live births. First-trimester screening for fetal abnorm-
alities is rapidly spreading in this region in consequence of
the regular theoretical and practical training of the obstetric
health care personnel therefore we were interested in looking
at the current prediction rate of fetal CHDs by means of an
increased NT in chromosomally normal fetuses.
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2. Methods
The pre- and postnatal findings, the course and outcome of
the pregnancies and the relationship between the first-tri-
mester fetal NT thickness and fetal CHDs were retrospec-
tively analyzed in 4309 pregnancies which ended either in
birth or therapeutic abortion at the Department of Obstetrics
and Gynecology, University of Szeged between January
1998 and June 2000.
The NT screening was performed by using a 6.5–7.5 MHz
vaginal probe (Kretz Technik Combison 530, 3D). The NT
thickness was measured at 10–13 weeks according to an
international agreement suggested by the Fetal Medicine
Foundation, London [15]. In summary, looking at and jud-
ging the nuchal contour and to distinguish between fetal skin
and amnion in moving fetuses, the NT measurement was
performed in quiet anteflexed embryos in saggittal section.
The largest screen magnification was used and the maximum
thickness of the subcutaneous translucency was measured
using ‘‘on to on’’ position of the callipers. Second-trimester
ultrasound evaluation was performed as routine prenatal
surveillance at weeks [18–20]. Informed consent was
obtained and all the women participated in the ultrasound
study voluntarily.
The Prenatal Clinic of the University is a tertiary center
where regular theoretical and practical training sessions are
organized twice a year to teach first-trimester NT screening
and fetal evaluation to obstetricians and sonographers. NT
measurement is now being more routinely performed due to
increased availability in the ultrasound labs of the hospital in
the region of Szeged. However, not in all hospitals, so it is
possible for women to deliver at our department without
having had first-trimester NT measurement.
Newborns were examined on the first and fourth postnatal
days by a neonatologist. In the event of any clinical sign of
CHDs (i.e. cyanosis, a murmur, an increased oxygen
Table 1
First-trimester nuchal translucency (NT) thickness and the crown-rump length in neonates with major defects of heart and great vesselsa
No. NT thickness (mm) CRL Cardiac defects Gestational age (weeks) Outcome
1 5 63 ASD, PS 39 NICU
2 4.8 43 ASD 38 CCC
3 4.3 42 Tetralogy of Fallot 32 Intrauterine death
4 4.2 39 VSD 40 CCC
5 4.1 55 VSD 40 CCC
6 4 62 Hypoplastic left heart syndrome 40 NICU, death
7 4 40 Hypoplastic left heart syndrome 37 NICU, death
8 3.5 37 ASD, club-foot 39 CCC
9 3.4 37 ASD 36 CCC
10 3.4 40 ASD, PDA 39 CCC
11 3.2 43 ASD 36 CCC
12 3.2 42 Tetralogy of Fallot 38 NICU
13 3.1 41 ASD 40 CCC
14 3.1 48 Tetralogy of Fallot 40 NICU
15 3 45 Aortic stenosis 39 NICU
16 2.4 39 ASD, PDA 40 CCC
17 2.3 45 ASD 36 CCC
18 2.1 55 VSD 37 CCC
19 2.1 43 PDA 40 CCC
20 2 50 Transposition of pulmonary vein 40 NICU
21 1.9 51 Tetralogy of Fallot 41 NICU
22 1.7 39 Transposition of pulmonary vein 38 NICU, death
23 1.6 42 VSD 39 CCC
24 1.6 34 ASD, VSD 39 CCC
25 1.5 49 Tetralogy of Fallot 39 NICU
26 1.5 38 VSD 40 CCC
27 1.4 43 Tetralogy of Fallot 40 CCC
28 1.3 34 Transposition of great arteries 39 NICU
29 1.3 39 Hypoplastic left heart syndrome 37 NICU, death
30 1.2 45 AS, MS 39 NICU, death
31 1.2 45 ASD 39 CCC
32 0.9 37 PS 39 NICU
33 –b 50 Tetralogy of Fallot, hypospadiasis 39 NICU, death
34 – 63 ASD 38 CCC
35 – 38 VSD 41 CCC
36 – 43 ASD 39 CCC
a ASD: atrial septal defect, VSD: ventricular septal defect, PDA: patent ductus arteriosus, PS: pulmonary stenosis, MS: mitral stenosis, AS: aortic
stenosis, NICU: neonatal intensive care unit, CCC: continuous cardiac control.
b Not measured.
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requirement or fatigue), a pediatric cardiologist was
involved in exploring the diagnosis.
3. Results
Between January 1998 and June 2000, 4251 births and 58
therapeutic abortions (altogether 4309 pregnancies) were
recorded at our Department of Obstetrics and Gynecology.
At birth, 151 congenital malformations were diagnosed; 34
of them were known prenatally. In the 58 pregnancies ending
with therapeutic abortion, there were 22 fetal chromosomal
abnormalities, 19 neural tube defects and 17 severe multiple
fetal malformations. Altogether, 209 (4.9%) congenital
malformations were detected, 39 (18.7%) of which were
CHDs. Eight of the 39 CHDs were diagnosed by fetal
echocardiography, while the others were suspected on neo-
natal examination and were confirmed by ultrasonography.
The prevalence of major CHDs was 9 per 1000 pregnancies
(39/4309).
First-trimester fetal NT measurement was available in 35
of the 39 fetuses with CHDs: it was 3 mm in 18 (51.4%)
and <3 mm in 17 (48.6%) (Tables 1 and 2). Table 1 shows the
crown-rump length at which the NT thickness was measured
in 36 pregnancies. The types of CHDs, the gestational age in
weeks at term and the outcomes are also listed. The NT was
not measured in four fetuses with CHDs. The NT thickness
was 3 mm in 15 and 2 mm in 20 of 32 fetuses with
CHDs. Table 2 presents data on three additional fetuses with
prenatally detected severe CHDs combined with other
structural abnormalities. The NT thickness was >3 mm in
all three cases. With regard to the virtual certainty of
extremely unfavorable outcomes of these three pregnancies,
therapeutic abortion was offered (after careful and extensive
non-directive counseling) by members of the University
Fetal Board (obstetrician–sonographer, pediatric cardiolo-
gist, neonatologist, heart surgeon and geneticist). In all three
cases, the couples opted for therapeutic abortion, which was
performed in weeks 17, 22 and 23, respectively. Autopsy
confirmed the prenatal findings.
First-trimester NT thicknesses of 3 or 2 mm or more were
found in 18 (51.4%) and in 23 (72%), respectively, of the 35
fetuses with CHDs.
The CHDs were classified into five main groups: hypo-
plastic left heart; ventricular and atrial septal defects; tetral-
ogy of Fallot; transposition of the great vessels; and others
(Table 3). An increased first-trimester NT was found pre-
dominantly in fetuses with defects in the left heart tract
(75%) or with atrial and ventricular septal defects (58.8%).
All fetuses with transposition of the great vessels had a NT
<3 mm. The numbers indicate only the tendency, and are
insufficient for a statistical evaluation.
A sensitivity of 51.4%, a specificity of 97.6%, a positive
predictive value of 17.8%, a negative predictive value of
99.5% and a false positive rate of 4.1% were found at cutoff
of 3 mm (Table 4). The measurement of increased nuchal
translucency (NT) for the detection of fetal cardiac abnorm-
alities had a sensitivity of 51.4 and 71.9% at a cutoff of 3 and
2 mm, respectively.
The outcomes of pregnancies involving fetal CHDs are
detailed in Table 5. The mean neonatal birth weight was
3141 549:72 g and the mean neonatal gestational age was
Table 2
First-trimester nuchal translucency (NT) thickness and crown-rump length in fetuses who underwent therapeutic abortion because of severe cardiac and other
structural abnormalitiesa
No. NT thickness
(mm)
CRL Fetal abnormalities Gestational
age (weeks)
Outcome
1 4.8 42 VSD, hernia diaphragmatica, hypoplastic left lung 23 TOP
2 4.2 38 Hypoplastic left heart syndrome, dextrocardia 22 TOP
3 3.2 39 Congenital cardiomyopathy, bilateral renal agenesis,
pulmonary hypoplasia, esophageal atresia, micropenis
17 TOP
a VSD: ventricular septal defect, CRL: crown-rump length, TOP: termination of pregnancy.
Table 3
Detection of specific cardiac defects using a nuchal translucency cutoff of 3 mm
Cardiac defect No. of fetuses Nuchal translucency thickness Detection rate (%)
<3 mm 3 mm
Hypoplastic left heart 4 1 3 75
Atrial and ventricular septal defects 20a 7 10 58.8
Tetralogy of Fallot 7b 3 3 50
Transposition of great vessels 3 3 0 0
Other defects 5 3 2 40
Total 39 17 18 51.4
a Three cases were not measured.
b One case was not measured.
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38:83 1:34 weeks. There were 24 (66.7%) spontaneous
deliveries, one (2.8%) forceps delivery and 11 (30.6%)
cesarean sections. The rates of premature delivery and IUGR
were 11.1 and 16.7%, respectively. The 5 min Apgar score
was <7 in only one (2.8%) case. The umbilical cord blood
pH was less than 7.2 in 10 (27.8%) cases. Fifteen newborns
(41.7%) were transferred to the Neonatal Intensive Care
Unit (NICU). Two neonates underwent heart surgery in the
first week and another two during the first year. Three babies
(8.3%) died in the perinatal period, and four (11.1%) during
the first year of life, resulting in perinatal and neonatal
mortalities of 8.3% (3/36) and 11.1% (4/36), respectively.
4. Discussion
Screening for CHDs at the earliest possible stage of
gestation is an important task, but a great challenge in
prenatal diagnostics. Fetal echocardiography in the second
or (more recently) the first-trimester of pregnancy has been
found to be a promising screening method for CHDs.
Evaluation of the four-chamber view of the heart and the
outflow tracts in the second-trimester of pregnancy yielded a
sensitivity as high as 61% [4,5].
An earlier and a higher rate of detection of fetal CHDs was
found when ultrasound measurement of increased fetal NT
thickness (3 mm) at weeks 10–13 of gestation was demon-
strated to be associated with fetal cardiac malformations
[9,12–15]. The findings in most of the publications are in
accord from this respect, but Schwa¨rzler et al. were not able
to confirm such an association in an unselected population
[18].
4.1. Cutoff
The prevalence of major CHDs increases in parallel with
the NT thickness [12–14] and Zosmer et al. suggest the 95th
centile of NT thickness as a cutoff at which the follow-up of
such pregnancies by sonographers and specialists in fetal
echocardiography is recommended. Our data indicate that
screening on the basis of an increased NT thickness, with a
cutoff of 3 mm, identifies 51.4% of the major abnormalities
of the heart and great arteries at weeks 10–13 of gestation.
The results compare favorably with the data reported by
Hyett et al. [12,13]. An even higher detection rate of 71.9%
(23/32) can be obtained at a cutoff value of 2 mm. Since
the rate of a NT thickness >3 mm in the general population is
between 2 and 3%, ultrasound follow-up of these selected
pregnancies means an extra load for specialists in fetal
echocardiography. If we use a lower cutoff, we can detect
more fetal CHDs, but the workload will increase signifi-
cantly. A practically acceptable cutoff value is therefore
necessary to distinguish cases marked for follow-up. It is
known that the NT thickness normally increases with crown-
rump length and the 95th centile is 2.2 mm for a crown-rump
length of 38 and 2.8 mm for a crown-rump length of 84 mm
[13], and the use of a single cutoff may bias the sensitivity.
We consider that 3 mm cutoff yielding 51% sensitivity is
practically acceptable, especially if the NT screening con-
centrate on between weeks 11 and 12.
4.2. Types of fetal CHDs screenable via an increased NT
We found an association between the type of fetal CHDs
and an increased NT. A hypoplastic left heart and septal
defects displayed stronger associations with an increased
NT. This observation is comparable with previous reports of
the highest detection rate in cases involving a hypoplastic
left heart syndrome [14,15].
4.3. Follow-up and clinical management of pregnancies
with an increased NT and a normal karyotype
An increased fetal NT thickness at weeks 10–13 of
gestation is associated with fetal aneuploidies [10,11], car-
diac [11–14] and other structural abnormalities [15] and
certain genetic syndromes [15,16]. Since an increased NT
accompanies such a wide range of fetal abnormalities,
careful clinical management should be observed. Our policy
is first to determine the fetal karyotype; in chromosomally
Table 4
Sensitivity, specificity, positive and negative predictive values, and false
positive rate of screening for major defects of heart and great vessels using
3 mm nuchal translucency cutoff
Using 3 mm cutoff level (%)
Sensitivity 51.4
Specificity 97.7
Positive predictive value 17.8
Negative predictive value 99.5
False positive rate 4.05
Table 5
Outcome of 36 pregnancies with fetal cardiac defectsa
No. %
Mode of delivery
Spontaneous vaginal 24 66.6
Operative vaginal 1 2.8
Cesarean section 11 30.6
Premature labor 4 11.1
IUGRb 6 16.7
Apgar score at 5 min <7 1 2.8
Umbilical cord pH <7.20 10 27.8
Neonatal intensive care admission 15 41.7
Cardiac defects operated on in the first week 2 5.6
Cardiac defects operated on in the first year 2 5.6
Perinatal mortality 3 8.3
Neonatal mortality 4 11.1
a Birth weight (g) (mean  S.D.) ¼ 3141.71  549.72; gestational age
at birth (weeks) (mean  S.D.) ¼ 38.83  1.34.
b IUGR: intrauterine growth retardation.
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normal fetuses, a thorough ultrasound follow-up is recom-
mended, including targeted fetal echocardiography and
scanning for structural abnormalities and genetic syn-
dromes.
Spontaneous resolution of nuchal edema occurs in 90% of
pregnancies with an increased NT and a normal karyotype.
These pregnancies will result in normal neonates [19]. Only
the remaining 10% of fetuses with an increased NT need
further evaluation (with targeted fetal echocardiography),
which does not mean too great an overload for the medical
personnel.
Though the issue of whether the antenatal diagnosis of
CHDs affects the postnatal outcome is still controversial,
most authors favor an early prenatal diagnosis to avoid long-
term cardiac and neurological consequences. Newborns with
cardiac abnormalities should be born in hospitals where all
appropriate cardiological facilities are available. Adequate
care can then be provided in due time for the neonatal
cardiac patient.
In conclusion, an increased fetal NT thickness at weeks
10–13 was found to be an important predictor and efficient
method of screening not only for fetal aneuploidies [15,20],
but also for fetal cardiac defects [14,15]. Furthermore, an
increased NTof3 mm can be regarded a selection criterion
for early second-trimester targeted fetal echocardiography
and for increased fetal and neonatal surveillance.
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